Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

635
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
635
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Retroviruses02:33

Retroviruses

14.5K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.

The Lancet. Microbe·2026
Same author

Prospective multicentre study of upper respiratory mucosal transcriptomics reveals two major endotypes of critically ill COVID-19 patients.

Communications medicine·2026
Same author

Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Hepatitis C virus elimination: So close, so far?

Antiviral research·2026
Same author

Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Open forum infectious diseases·2026

Related Experiment Video

Updated: Dec 30, 2025

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.3K

Interferon-Free Hepatitis C Virus Therapy.

Jean-Michel Pawlotsky1,2

  • 1National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, 94010 Créteil, France.

Cold Spring Harbor Perspectives in Medicine
|January 23, 2020
PubMed
Summary

Hepatitis C virus (HCV) infection affects millions globally. New direct-acting antiviral drugs offer a promising path toward HCV elimination by 2030, but improved screening and access to care are crucial.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.0K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Related Experiment Videos

Last Updated: Dec 30, 2025

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.3K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.0K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection is a significant global health issue, causing chronic liver disease in approximately 71 million people worldwide.
  • Chronic HCV infection is a leading cause of liver cirrhosis and hepatocellular carcinoma.

Purpose of the Study:

  • To review the advancements in Hepatitis C virus treatment.
  • To discuss the potential for HCV elimination as a public health threat.
  • To highlight the role of international guidelines and new therapies in achieving HCV eradication.

Main Methods:

  • Review of current scientific literature and treatment guidelines from major international health organizations.
  • Analysis of the efficacy, safety, and resistance profiles of newly developed direct-acting antiviral (DAA) drugs.
  • Assessment of global HCV epidemiology and the impact of treatment accessibility.

Main Results:

  • Direct-acting antiviral (DAA) drug combinations represent a significant therapeutic advancement, offering high cure rates, safety, and tolerability with a high barrier to resistance.
  • International guidelines from organizations like EASL, AASLD/IDSA, and WHO recommend these DAA regimens for HCV treatment.
  • The widespread availability of effective treatments makes the elimination of Hepatitis C virus as a public health threat by 2030 a feasible goal in many countries.

Conclusions:

  • Highly effective direct-acting antiviral therapies have transformed Hepatitis C virus management.
  • Achieving global Hepatitis C virus elimination by 2030 requires not only treatment accessibility but also enhanced screening, diagnosis, and linkage to care strategies.
  • Continued global efforts are essential to combat the public health burden of Hepatitis C virus infection.